160 related articles for article (PubMed ID: 1370198)
1. Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder.
Altemus M; Pigott T; Kalogeras KT; Demitrack M; Dubbert B; Murphy DL; Gold PW
Arch Gen Psychiatry; 1992 Jan; 49(1):9-20. PubMed ID: 1370198
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder.
Swedo SE; Leonard HL; Kruesi MJ; Rettew DC; Listwak SJ; Berrettini W; Stipetic M; Hamburger S; Gold PW; Potter WZ
Arch Gen Psychiatry; 1992 Jan; 49(1):29-36. PubMed ID: 1370197
[TBL] [Abstract][Full Text] [Related]
3. Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine.
Altemus M; Swedo SE; Leonard HL; Richter D; Rubinow DR; Potter WZ; Rapoport JL
Arch Gen Psychiatry; 1994 Oct; 51(10):794-803. PubMed ID: 7524463
[TBL] [Abstract][Full Text] [Related]
4. Vasopressin in CSF and plasma in depressed suicide attempters: preliminary results.
Brunner J; Keck ME; Landgraf R; Uhr M; Namendorf C; Bronisch T
Eur Neuropsychopharmacol; 2002 Oct; 12(5):489-94. PubMed ID: 12208567
[TBL] [Abstract][Full Text] [Related]
5. Plasma and cerebrospinal fluid measures of arginine vasopressin secretion in patients with bulimia nervosa and in healthy subjects.
Demitrack MA; Kalogeras KT; Altemus M; Pigott TA; Listwak SJ; Gold PW
J Clin Endocrinol Metab; 1992 Jun; 74(6):1277-83. PubMed ID: 1592871
[TBL] [Abstract][Full Text] [Related]
6. Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Comparison with Tourette's syndrome and healthy controls.
Leckman JF; Goodman WK; North WG; Chappell PB; Price LH; Pauls DL; Anderson GM; Riddle MA; McSwiggan-Hardin M; McDougle CJ
Arch Gen Psychiatry; 1994 Oct; 51(10):782-92. PubMed ID: 7524462
[TBL] [Abstract][Full Text] [Related]
7. Abnormalities in plasma and cerebrospinal-fluid arginine vasopressin in patients with anorexia nervosa.
Gold PW; Kaye W; Robertson GL; Ebert M
N Engl J Med; 1983 May; 308(19):1117-23. PubMed ID: 6835335
[TBL] [Abstract][Full Text] [Related]
8. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects.
Thorén P; Asberg M; Bertilsson L; Mellström B; Sjöqvist F; Träskman L
Arch Gen Psychiatry; 1980 Nov; 37(11):1289-94. PubMed ID: 6159865
[TBL] [Abstract][Full Text] [Related]
9. CSF somatostatin in obsessive-compulsive disorder.
Altemus M; Pigott T; L'Heureux F; Davis CL; Rubinow DR; Murphy DL; Gold PW
Am J Psychiatry; 1993 Mar; 150(3):460-4. PubMed ID: 8094599
[TBL] [Abstract][Full Text] [Related]
10. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls.
Chappell P; Leckman J; Goodman W; Bissette G; Pauls D; Anderson G; Riddle M; Scahill L; McDougle C; Cohen D
Biol Psychiatry; 1996 May; 39(9):776-83. PubMed ID: 8731518
[TBL] [Abstract][Full Text] [Related]
11. Vasopressin-dependent flank marking in golden hamsters is suppressed by drugs used in the treatment of obsessive-compulsive disorder.
Ferris CF; Rasmussen MF; Messenger T; Koppel G
BMC Neurosci; 2001; 2():10. PubMed ID: 11545675
[TBL] [Abstract][Full Text] [Related]
12. Secretion of corticotropin releasing factor (CRF) and vasopressin (AVP) into the hypophysial portal blood of conscious, unrestrained rams.
Caraty A; Grino M; Locatelli A; Oliver C
Biochem Biophys Res Commun; 1988 Sep; 155(2):841-9. PubMed ID: 3048263
[TBL] [Abstract][Full Text] [Related]
13. Effect of plasma osmolality on pituitary-adrenal responses to corticotropin-releasing hormone and atrial natriuretic peptide changes in central diabetes insipidus.
Elias LL; Antunes-Rodrigues J; Elias PC; Moreira AC
J Clin Endocrinol Metab; 1997 Apr; 82(4):1243-7. PubMed ID: 9100602
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls.
Pitts AF; Samuelson SD; Meller WH; Bissette G; Nemeroff CB; Kathol RG
Biol Psychiatry; 1995 Sep; 38(5):330-5. PubMed ID: 7495928
[No Abstract] [Full Text] [Related]
15. Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophysial portal blood.
Gibbs DM; Vale W
Brain Res; 1983 Nov; 280(1):176-9. PubMed ID: 6317143
[TBL] [Abstract][Full Text] [Related]
16. Enhanced monoaminergic neurotransmission by desglycinamide-arginine-vasopressin in human subjects.
Jolkkonen J; Lehtinen M; Soininen H; Sennef C; Riekkinen P
Neurosci Lett; 1987 May; 76(3):312-5. PubMed ID: 2438607
[TBL] [Abstract][Full Text] [Related]
17. Effect of administration of corticotropin-releasing hormone and glucocorticoid on arginine vasopressin response to osmotic stimulus in normal subjects and patients with hypocorticotropinism without overt diabetes insipidus.
Yamada K; Tamura Y; Yoshida S
J Clin Endocrinol Metab; 1989 Aug; 69(2):396-401. PubMed ID: 2546964
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects.
Fossey MD; Lydiard RB; Ballenger JC; Laraia MT; Bissette G; Nemeroff CB
Biol Psychiatry; 1996 Apr; 39(8):703-7. PubMed ID: 8731457
[TBL] [Abstract][Full Text] [Related]
19. Cortisol in the CSF of depressed and suicidal patients.
Träskman L; Tybring G; Asberg M; Bertilsson L; Lantto O; Schalling D
Arch Gen Psychiatry; 1980 Jul; 37(7):761-7. PubMed ID: 6156664
[TBL] [Abstract][Full Text] [Related]
20. Plasma catecholamines and their metabolites in obsessive-compulsive disorder.
Benkelfat C; Mefford IN; Masters CF; Nordahl TE; King AC; Cohen RM; Murphy DL
Psychiatry Res; 1991 Jun; 37(3):321-31. PubMed ID: 1891512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
